Anti-Infectives Industry Gathers in 3 Weeks to Combat Superbugs at 18th Annual Summit
At the forefront of combating the serious global threat of antimicrobial resistance (AMR) for almost two decades, the infectious disease industry's premier event returns to London next month on 16th and 17th March.
London, United Kingdom, February 25, 2016 --(PR.com)-- SMi Group are delighted to announce that the 18th annual Superbugs & Superdrugs event is shaping up to be the biggest event to date. With registration closing in just 3 weeks, those who are interested in registering are advised to do so soon before places sell out.
Highlights on the agenda for Superbugs & Superdrugs 2016 include:
1. Current Status: Progressive insight into current developments in big pharma with updates on new economic models. What can we expect in the next 10 years and how much will it cost?
2. The Global Plan: Attendees will hear BARDA's exclusive keynote address on funding opportunities and discover how the US plans to combat antibiotic resistant infections. This will be followed by a second keynote from the European Commission on the EU's action plan on AMR.
3. Collaboration: With a aim in strengthening antibiotic pipelines, the programme will include presentations on strategic partnerships and collaborations.
4. Clinical Results: Stage 3 clinical updates will be given on an antibiotic with potential use in multiple therapeutics indications.
5. AMR in Healthcare: The agenda discusses the role of touch surfaces in the acquisition on infection and the spread of AMR.
6. Incentives: Superbugs 2016 will look to accelerate drug development and diagnostic tools with insight into the EU project INFECT. Attendees will also learn about new in vitro models to understand drug resistance at the tissue site of infection.
7. Prepare: The industry learns how to prepare for outbreaks with case study insights into the application of genome sequencing as a gold standard approach for molecular strain typing; rapid diagnosis of drug resistant forms of TB; and companion diagnostics for support od MDR infectious disease control.
8. Regulatory Guidance: The conference will determine preclinical PK/PD relationships for optimising dosage requirements for new and existing drugs with regulatory recommendations.
This is just a snapshot of what will be included on the agenda for 2016.
Other key topics discussed include: mAb products targeting MDR gram negative infections; clinical applications into achieving antibiotic sensitivity and resistance prevention; protecting the human microbiome; antimicrobial peptides; combination therapy plus much more!.
Hear is what this years attendee's are saying in the run up to the show:
- "I have attended this conference for many years. It has always been at the forefront, providing insight into novel developments, and exciting discussions. One of my favourites.” - Da Volterra
- "New classes of antibiotics and early stage programs. These could be in-licensing opportunities for Cempra. New classes of antibiotics are badly needed." - Cempra's event highlight.
- "I am expecting that attendees will gain a greater understanding of how BARDA enters into strategic partnerships with industry to advance the development of promising products to counter the growing global threat of antimicrobial resistance." – Barda's interest in future partnerships.
- "The conference agenda has been drafted with great care to give you the very best opportunity to benchmark and learn from subject matter experts in infectious diseases, health economics and advanced technologies and solutions. Networking and learning with our peers is the secret to improving the drug development pipeline. With practical case studies and interactive roundtables, there is confidence that we will be able to crack the ‘chicken or the egg’ problem." - The conference Chairing Committee from Transcrip Partners and Chemical Biology Ventures
Further information is available to download online at www.superbugssuperdrugs.com/prcom
Superbugs & Superdrugs 2016
16 - 17 March 2016 | Holiday Inn Kensington Forum, London UK
www.superbugssuperdrugs.com/prcom
Highlights on the agenda for Superbugs & Superdrugs 2016 include:
1. Current Status: Progressive insight into current developments in big pharma with updates on new economic models. What can we expect in the next 10 years and how much will it cost?
2. The Global Plan: Attendees will hear BARDA's exclusive keynote address on funding opportunities and discover how the US plans to combat antibiotic resistant infections. This will be followed by a second keynote from the European Commission on the EU's action plan on AMR.
3. Collaboration: With a aim in strengthening antibiotic pipelines, the programme will include presentations on strategic partnerships and collaborations.
4. Clinical Results: Stage 3 clinical updates will be given on an antibiotic with potential use in multiple therapeutics indications.
5. AMR in Healthcare: The agenda discusses the role of touch surfaces in the acquisition on infection and the spread of AMR.
6. Incentives: Superbugs 2016 will look to accelerate drug development and diagnostic tools with insight into the EU project INFECT. Attendees will also learn about new in vitro models to understand drug resistance at the tissue site of infection.
7. Prepare: The industry learns how to prepare for outbreaks with case study insights into the application of genome sequencing as a gold standard approach for molecular strain typing; rapid diagnosis of drug resistant forms of TB; and companion diagnostics for support od MDR infectious disease control.
8. Regulatory Guidance: The conference will determine preclinical PK/PD relationships for optimising dosage requirements for new and existing drugs with regulatory recommendations.
This is just a snapshot of what will be included on the agenda for 2016.
Other key topics discussed include: mAb products targeting MDR gram negative infections; clinical applications into achieving antibiotic sensitivity and resistance prevention; protecting the human microbiome; antimicrobial peptides; combination therapy plus much more!.
Hear is what this years attendee's are saying in the run up to the show:
- "I have attended this conference for many years. It has always been at the forefront, providing insight into novel developments, and exciting discussions. One of my favourites.” - Da Volterra
- "New classes of antibiotics and early stage programs. These could be in-licensing opportunities for Cempra. New classes of antibiotics are badly needed." - Cempra's event highlight.
- "I am expecting that attendees will gain a greater understanding of how BARDA enters into strategic partnerships with industry to advance the development of promising products to counter the growing global threat of antimicrobial resistance." – Barda's interest in future partnerships.
- "The conference agenda has been drafted with great care to give you the very best opportunity to benchmark and learn from subject matter experts in infectious diseases, health economics and advanced technologies and solutions. Networking and learning with our peers is the secret to improving the drug development pipeline. With practical case studies and interactive roundtables, there is confidence that we will be able to crack the ‘chicken or the egg’ problem." - The conference Chairing Committee from Transcrip Partners and Chemical Biology Ventures
Further information is available to download online at www.superbugssuperdrugs.com/prcom
Superbugs & Superdrugs 2016
16 - 17 March 2016 | Holiday Inn Kensington Forum, London UK
www.superbugssuperdrugs.com/prcom
Contact
SMi Group
Teri Arri
+44 (0)20 7827 6162
www.superbugssuperdrugs.com/prcom
Teri Arri
+44 (0)20 7827 6162
www.superbugssuperdrugs.com/prcom
Contact
Categories